The hENT1 inhibitor, NBMPR, decreased sensitivity to GEM in bladder cancer cells and increased sensitivities to SZY-200 and CP-4126 (Figures 3B-D). The gene discussed is SLC29A1; the disease is urinary bladder carcinoma.